AFX-9901

AFX-9901 is a preclinical-stage small molecule therapeutic candidate being developed by Afecta Pharmaceuticals. It is specifically targeted for the treatment of obstetric (OB) hemorrhage, a potentially life-threatening condition characterized by heavy bleeding during or after childbirth. While the specific molecular target and mechanism of action have not been publicly disclosed by the developer, the program is part of Afecta's pipeline focused on addressing critical unmet needs in maternal health and emergency medicine. As a small molecule, AFX-9901 is likely designed for rapid intervention in clinical settings where managing excessive uterine bleeding is paramount.